The Science & Practice
Ibogaine Medicine
Ibogaine is the most pharmacologically complex psychedelic medicine known. Its safe and effective application requires a physician who understands not just the molecule, but the patient. Dr. Juan José Arellano has administered over 900 treatments — and built his practice on this principle.
What Is Ibogaine?
Ibogaine is a naturally occurring psychoactive compound derived from the Tabernanthe iboga plant, native to Central Africa, where it has been used in the Bwiti tradition for centuries. In the clinical context, ibogaine HCl — pharmaceutical-grade ibogaine hydrochloride — is the form Dr. Juan José Arellano administers with precisely calculated dosing.
What distinguishes ibogaine from every other treatment for addiction, PTSD, or depression is its mechanism of action. It does not simply manage symptoms. It acts directly on the opioid receptor system, resets dopaminergic function, upregulates GDNF (a neuroprotective protein), and produces profound neuroplastic changes — all simultaneously, in a single treatment session.
The clinical implications are remarkable. Opioid patients who have experienced years of failed conventional treatment — methadone, buprenorphine, naltrexone — arrive at MindScape and leave, days later, with opioid receptor systems that function differently. The physical craving mechanism is interrupted at its neurological source.
This does not make ibogaine a simple solution. The cardiac risk is real. The experience it produces — a 24 to 36 hour visionary and introspective journey — is profound and psychologically demanding. Its interactions with other substances and medications require meticulous management. These are the reasons that medical supervision is not optional — it is the foundation of safe ibogaine practice.
Pharmacology
How Ibogaine Works
Six primary mechanisms, all acting simultaneously — which is why ibogaine produces outcomes no single-mechanism drug can replicate.
Opioid Receptor Reset
Ibogaine is a potent kappa and mu-opioid receptor agonist that fundamentally resets the opioid receptor system. This mechanism is why patients experience dramatic reduction or elimination of withdrawal symptoms within hours of administration — the receptors are cleared and normalized at the neurological level.
GDNF Upregulation
Ibogaine increases expression of GDNF (Glial Cell Line-Derived Neurotrophic Factor), a protein essential for the survival and repair of dopaminergic neurons. This is the basis for its applications in Parkinson's disease and treatment-resistant depression, where neuronal repair drives lasting clinical improvement.
Sigma-2 Receptor Activity
Ibogaine's interaction with sigma-2 receptors produces the characteristic visionary and introspective phases of the experience. This receptor activity facilitates the deep psychological processing that distinguishes ibogaine from purely pharmacological interventions — and explains why integration therapy amplifies outcomes.
Noribogaine — The Long-Term Metabolite
Ibogaine metabolizes into noribogaine, which remains active in the body for 2–3 months post-treatment. Noribogaine continues to modulate opioid receptors and maintain anti-craving effects long after the acute session, making the ibogaine experience a sustained pharmacological intervention rather than a single acute event.
Serotonin Reuptake Inhibition
Ibogaine also inhibits serotonin and dopamine transporters, contributing to its antidepressant effects and explaining why SSRI discontinuation must be carefully managed. This serotonergic activity requires precise protocol design to avoid dangerous drug interactions.
Cardiac Risk & QTc Prolongation
Ibogaine prolongs the cardiac QTc interval — a real and manageable risk that demands pre-treatment EKG screening, electrolyte optimization, and continuous cardiac telemetry throughout the session. This is why ibogaine must be administered by a physician with cardiac monitoring infrastructure, not in a ceremonial setting.
Clinical Protocol
Dr. Juan José Arellano's Treatment Protocol
Six stages. Every step physician-led. The rigor is not incidental — it is the foundation of outcomes.
Comprehensive Medical Screening
12-lead EKG, complete blood count, comprehensive metabolic panel, liver function tests, electrolyte panel, and thorough medical history review. Dr. Juan José Arellano personally reviews all screening results before approving any patient for treatment.
Individualized Protocol Design
No standardized dosing. Dr. Juan José Arellano designs each protocol based on body weight, metabolic profile, substance history, psychiatric presentation, and cardiac assessment. This individualization is what separates clinical ibogaine medicine from ceremonial or underground administration.
Pre-Treatment Preparation
Dietary preparation, substance taper schedule (critical for opioids, SSRIs, benzodiazepines), psychological preparation, intention-setting, and final medical clearance. The preparation phase directly impacts treatment outcomes.
Medically Supervised Treatment Session
Ibogaine administration with continuous cardiac telemetry, IV access maintained, pulse oximetry, 1:1 nursing ratio, and Dr. Juan José Arellano's direct oversight throughout the 24–36 hour session. The medical infrastructure is equivalent to an outpatient clinical setting.
Post-Session Medical Observation
Continuous monitoring through the residual stimulation phase. Vital signs, cardiac rhythm, hydration, and neurological status are tracked until the patient is medically stable. This phase is often underestimated — Dr. Juan José Arellano considers it as important as the session itself.
Structured Integration Plan
Every patient leaves with a personalized 90-day integration roadmap: scheduled check-in calls, psychological support referrals, lifestyle guidance, and access to the MindScape alumni community. Integration determines whether neurological reset becomes lasting change.
Ibogaine carries real cardiac risk. It must not be administered outside a medical setting with physician oversight and continuous cardiac monitoring.
Underground, ceremonial, or self-administered ibogaine is dangerous. Every patient who has died from ibogaine did so outside a proper clinical setting. Dr. Juan José Arellano's protocols — EKG screening, electrolyte optimization, continuous telemetry — exist precisely to prevent these outcomes.
Start with a Safe Consultation →